Causes and Treatment Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in 82 Adult Patients
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are predominantly known as medication-induced diseases. However, at our institution, we have experienced more cases of non-drug-related SJS and TEN than expected. Therefore, we studied the difference between non-drug-related and drug-related SJS and TEN in terms of clinical characteristics and prognoses. Methods: The etiologies, clinical characteristics, and treatment outcomes for 82 adult patients with SJS and TEN were retrospectively reviewed. Results: A total of 71 patients (86.6%) were classified as having SJS, and the other 11 patients (13.4%) were classified as having TEN. Drug-related cases were more common (43, 52.4%) than non-drug-related cases (39, 47.6%). Anticonvulsants (12/82, 14.6%) and antibiotics (9/82, 11%) were the most common causative medications. Anemia (p = 0.017) and C-reactive protein of ≥ 5 mg/dL (p = 0.026) were more common in the drug-related cases than in the nondrug-related cases. Intravenous steroid therapy was used as the main treatment regimen (70/82, 85.4%). Of the 82 patients, 8 (9.8%) died during the clinical course. A univariate analysis for mortality showed statistical significance for the following: kidney function abnormality, pneumonia, hemoglobin of < 10 g/dL, and combined underlying diseases. In a multivariate analysis, only pneumonia was statistically significant (odds ratio, 25.79; p = 0.009). Conclusions: Drugs were the most frequent cause of these diseases. However, non-drug-related causes also contributed to a significant proportion of cases. Physicians should keep this in mind when documenting patient history. In addition, early recognition and treatment may be important for better outcomes.
Abstract
Background/Aims: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are predominantly known as medication-induced diseases. However, at our institution, we have experienced more cases of non-drug-related SJS and TEN than expected. Therefore, we studied the difference between non-drug-related and drug-related SJS and TEN in terms of clinical characteristics and prognoses. Methods: The etiologies, clinical characteristics, and treatment outcomes for 82 adult patients with SJS and TEN were retrospectively reviewed. Results: A total of 71 patients (86.6%) were classified as having SJS, and the other 11 patients (13.4%) were classified as having TEN. Drug-related cases were more common (43, 52.4%) than non-drug-related cases (39, 47.6%). Anticonvulsants (12/82, 14.6%) and antibiotics (9/82, 11%) were the most common causative medications. Anemia (p = 0.017) and C-reactive protein of ≥ 5 mg/dL (p = 0.026) were more common in the drug-related cases than in the nondrug-related cases. Intravenous steroid therapy was used as the main treatment regimen (70/82, 85.4%). Of the 82 patients, 8 (9.8%) died during the clinical course. A univariate analysis for mortality showed statistical significance for the following: kidney function abnormality, pneumonia, hemoglobin of < 10 g/dL, and combined underlying diseases. In a multivariate analysis, only pneumonia was statistically significant (odds ratio, 25.79; p = 0.009). Conclusions: Drugs were the most frequent cause of these diseases. However, non-drug-related causes also contributed to a significant proportion of cases. Physicians should keep this in mind when documenting patient history. In addition, early recognition and treatment may be important for better outcomes.
참고문헌 (29)
- Borchers AT, "Stevens-Johnson syndrome and toxic epidermal necrolysis", Autoimmun Rev, 7, pp.598~605 (2008)
- Mockenhaupt M, "The current understanding of StevensJohnson syndrome and toxic epidermal necrolysis", Expert Rev Clin Immunol, 7, pp.803~813 (2011)
- Bachot N, "Differential diagnosis of severe cutaneous drug eruptions", Am J Clin Dermatol, 4, pp.561~572 (2003)
- Auquier-Dunant A, "Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study", Arch Dermatol, 138, pp.1019~1024 (2002)
- Tay YK, "Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra)", J Am Acad Dermatol, 35(5), pp.757~760 (1996)
- Mulvey JM, "Mycoplasma pneumonia associated with Stevens Johnson syndrome", Anaesth Intensive Care, 35, pp.414~417 (2007)
- Leigh IM, "Recurrent and continuous erythema multiforme: a clinical and immunological study", Clin Exp Dermatol, 10, pp.58~67 (1985)
- Bastuji-Garin S, "SCORTEN: a severity-of-illness score for toxic epidermal necrolysis", J Invest Dermatol, 115, pp.149~153 (2000)
- Schneck J, "Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study", J Am Acad Dermatol, 58, pp.33~40 (2008)
- Power WJ, "Analysis of the acute ophthalmic manifestations of the erythema multiforme", Stevens-Johnson syndrome, Ophthalmology, pp.1995, 102[DOI]
- Bastuji-Garin S, "Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme", Arch Dermatol, 129, pp.92~96 (1993)
- Rzany B, "Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990- 1992): structure and results of a population-based registry", J Clin Epidemiol, 49, pp.769~773 (1996)
- Chang YS, "Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management", Cornea, 26, pp.123~129 (2007)
- 김은정, "최근 5년간 광주, 전남 지역에서 발생한 Stevens-Johnson 증후군과 중독성 표피 괴사융해증의 임상적 고찰", 대한피부과학회지, 44(5), pp.574~578 (2006), 대한피부과학회
- Mockenhaupt M, "Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study", J Invest Dermatol, 128, pp.35~44 (2008)
- 이병재, "Comparison of the Causes and Clinical Features of Drug Rash With Eosinophilia and Systemic Symptoms and Stevens-Johnson Syndrome", Allergy, Asthma & Immunology Research, 2(2), pp.123~126 (2010), 대한천식알레르기학회
- Wetter DA, "Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic", Mayo Clin Proc, 85, pp.131~138 (2010)
- Revuz J, "Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients", Arch Dermatol, 123, pp.1160~1165 (1987)
- Correia O, "Evolving pattern of drug-induced toxic epidermal necrolysis", Dermatology, 186, pp.32~37 (1993)
- Stewart MG, "Head and neck manifestations of erythema multiforme in children", Otolaryngol Head Neck Surg, 111(3), pp.236~242 (1994)
- Khoo AK, "Toxic epidermal necrolysis in a burns centre: a 6-year review", Burns, 22, pp.275~278 (1996)
- Pushker N, "Stevens-Johnson syndrome in India-risk factors, ocular manifestations and management", Ophthalmologica, 214, pp.285~288 (2000)
- French LE, "Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding", Allergol Int, 55, pp.9~16 (2006)
- Pereira FA, "Toxic epidermal necrolysis", J Am Acad Dermatol, 56, pp.181~200 (2007)
- Kardaun SH, "Dexamethasone pulse therapy for Stevens-Johnson syndrome", toxic epidermal necrolysis, 2007, pp.87, 144~148
- Araki Y, "Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset", Am J Ophthalmol, 147, pp.1004~1011 (2009)
- Faye O, "Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date", Drugs, 65, pp.2085~2090 (2005)
- Brown KM, "Toxic epidermal necrolysis: does immunoglobulin make a difference?", J Burn Care Rehabil, 25, pp.81~88 (2004)
- Shortt R, "Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis", J Burn Care Rehabil, 25, pp.246~255 (2004)